// App-Quantinova.ai

: Characteristics of new users of aclidinium, aclidinium/formoterol, and other COPD medications in three European countries

Researchers

Presenter

  • Cristina Rebordosa

Principal Investigators

  • Annalisa Rubino

  • Anna Julia Witzleb

  • Morten Olesen

  • Estel Plana

  • Jaume Aguado

  • Nuria Saigi

  • Sami Z Daoud

  • Alejhandra Lei

  • Susana Perez-Gutthann

  • Tania Schink

  • Nina S Kristiansen

  • Anton Pottegard

  • Elena Rivero-Ferrer

Medical Centers

  • RTI Health Solutions, Barcelona, Spain

  • Astra Zeneca, Cambridge, United Kingdom

  • Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany

  • University of Southern Denmark, Odense, Denmark

  • AstraZeneca Gaithersburg, Gaithersburg, United States of America

  • AstraZeneca, Barcelona, Spain.

Locations

  • Spain

  • United Kingdom

  • Germany

  • Denmark

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Autoimmune (AI)

Disease

  • Asthma

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • LAS 34273

  • Formoterol

  • Tiotropium bromide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved